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AAV = adeno-associated virus; Ad5 = adenovirus serotype 5; APC = antigen-presenting cell; BMP = bone morphogenetic protein; IGF = insulin-
like growth factor; IL-1Ra = IL-1 receptor antagonist); MSC = mesenchymal stem cell; OPG = osteoprotegerin; RA = rheumatoid arthritis; SCID =
severe combined immunodeficiency; sTNF-R = soluble tumor necrosis factor receptor; TGF = transforming growth factor.
Available online http://arthritis-research.com/content/3/5/289
Introduction
The Second International Meeting on Gene and Cell Ther-
apies of Arthritis and Related Disorders was held in Mont-
pellier, France on May 17 and 18, hosted by Christian
Jorgensen (Montpellier, France). The previous meeting
was held in Washington, DC in December of 1998. What
was clearly evident from the second meeting is that the
field of gene therapy for bone and joint disorders has
grown considerably over the last two and a half years in
terms of both the number of investigators and the types of
approaches being developed. Several investigators have
shown that ex vivo or in vivo gene transfer is highly effec-
tive in blocking the development of arthritis or facilitating
repair of damage cartilage or bone. The feasibility of apply-
ing gene therapy for the treatment of arthritis in humans
was also demonstrated. Thus, gene therapy appears
poised to make significant contributions to the clinical
treatment of joint and bone diseases in the near future.
Vectors
The rate-limiting step for any gene therapy application is the
efficiency of gene transfer. Two approaches were dis-
cussed: direct, in vivo gene delivery and indirect, ex vivo
gene transfer using synovial fibroblasts, chondrocytes,
antigen-presenting cells (APCs), lymphocytes or mesenchy-
mal stem cells (MSCs). Although a number of presentations
discussed improvements in viral and nonviral vectors for
direct gene transfer to joints or to bone defects, no vector
yet appears ready to be used in in vivo clinical trials.
W van den Berg (Nijmegen, The Netherlands), P Robbins
(University of Pittsburgh, USA) and T Oligino (University of
Meeting report
Gene therapy moves forward — The Second International Meeting
on Gene and Cell Therapies of Arthritis and Related Disorders,
17–18 May 2001, Montpellier, France
Paul D Robbins*, Christian Jorgensen† and Christopher H Evans‡
* Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA, USA
† Lapeyronie University Hospital, 34295 Montpellier, France
‡ Center for Molecular Orthopaedics, Harvard Medical School, Boston, MA, USA
Correspondence: Paul D Robbins, PhD, Department of Molecular Genetics and Biochemistry, W1246 BST, University of Pittsburgh, Pittsburgh, 
PA 15261, USA. Tel +1 412 648 9268; fax +1 412 383 8837; e-mail probb@pitt.edu
Abstract
The field of gene therapy for bone and joint disorders has grown considerably over the last two and a
half years. Investigators have shown that ex vivo or in vivo gene transfer is highly effective in blocking
arthritis or facilitating repair of damaged cartilage or bone. The feasibility of applying gene therapy for
the treatment of arthritis in humans has also been demonstrated. Thus, gene therapy appears poised to
make significant contributions to the clinical treatment of joint and bone diseases in the near future.
Keywords: arthritis, bone, cartilage, clinical trial, gene therapy, vector
Received: 16 July 2001
Accepted: 16 July 2001
Published: 31 July 2001
Arthritis Res 2001, 3:289–292
© 2001 BioMed Central Ltd
(Print ISSN 1465-9905; Online ISSN 1465-9913)Arthritis Research    Vol 3 No 5 Robbins et al
Pittsburgh, USA) all presented evidence that adenoviral
vectors are able to infect murine and rabbit synovial tissue
as well as infecting infiltrating monocytes following injec-
tion into the joint space. Expression was transient,
however, and the induction of neutralizing antibodies pre-
vents repeat dosing. T Huizinga (Leiden University, The
Netherlands) also demonstrated that synovial fluid from
many rheumatoid arthritis (RA) patients contains neutraliz-
ing antibodies to adenovirus serotype 5 (Ad5), but that
there are only low levels of neutralizing antibodies to
certain serotypes of adenoviruses in the synovial fluids of
RA patients. In particular, Ad35 is able to infect human
synovial cells more efficiently than Ad5, but was not neu-
tralized by pre-existing antibodies in synovial fluids. P Yeh
(Aventis-Gencell, France) discussed strategies for target-
ing adenoviruses to particular cell types.
The properties of adeno-associated virus (AAV) were
described by AM Douar (Genthon, France). AAV also
appears to be able to infect cells in the joint space effi-
ciently, resulting in prolonged gene expression (R Hirsch,
University of Cincinnati, USA). Hirsch suggested,
however, that AAV fails to transduce murine synovium but
gives the appearance of doing so by transducing the adja-
cent muscle very effectively. Nevertheless, his data
suggested that human synovial fibroblasts support trans-
duction by AAV much more effectively than their murine
counterparts. Given the initial success of clinical trials
using AAV for gene transfer to muscle, there was opti-
mism that AAV could be useful for intra-articular gene
delivery as well as for systemic delivery of soluble proteins
following intra-muscular injection. Both Oligino and
Robbins reported that transgene expression following the
intra-articular injection of an AAV vector was progressively
lost during the course of 2–3 weeks. Expression could not
be restored by readministration of the same vector, possi-
bly because of the induction of neutralizing antibodies. It is
not yet known whether such antibodies would be directed
against the transgene or the virus. Immunotherapy for
arthritis may be achieved through intramuscular injection
of recombinant AAV that contains genes encoding anti-
inflammatory cytokines. F Apparailly (Montpellier, France)
reported the efficacy of viral IL-10 expression under the
control of a tetOn inducible promoter using an AAV con-
struct in collagen-induced arthritis, and M-C Boissier
(Bobigny, France) also reported efficacy in this model
using AAV–IL-4.
P Corbeau (Montpellier, France) discussed the develop-
ment of lentiviral vectors and their ability to transduce cul-
tures of human synovial fibroblasts, a finding in agreement
with data showing that an HIV-based lentiviral vector was
able to infect rat synovium following intra-articular IL-1
receptor antagonist (IL-1Ra) injection. Surprisingly high
levels of intra-articular transgene expression were
obtained (E Gouze, Harvard Medical School, USA).
Two laboratories (C Pitzalis, London, UK and P Robbins)
have initiated studies to identify peptides that can target
cells within the joint following systemic delivery or those
that are able to transduce synovial cells following intra-
articular delivery. These peptides could be used to deliver
therapeutic proteins, drugs and possible plasmids or viral
vectors to cells within the joint. Finally, the use of nonviral
vectors was also presented. Although a number of nonviral
vectors were able to transfect synovium in vivo following
intra-articular injection, the duration of gene expression (of
over 100 different nonviral formulations tested) was less
than 1 week, with some of the formulations inducing
inflammation (P Robbins). The ability to express soluble
proteins in the long term from muscle by electroporation of
the plasmid DNA encoding them was demonstrated by D
Scherman (Aventis Gencell, France). The muscle thus rep-
resents an attractive target for regulated systemic expres-
sion of IL-1Ra, soluble tumor necrosis factor receptors
(TNF-R) or IL-10, especially if naked plasmid DNA can be
used as the vector. The same electroporation technology
was used with remarkable success for in vivo gene deliv-
ery to chondrocytes, with up to 40% of chondrocytes from
the patella expressing the transgene for 3 months (P
Gillet, Vandoeuvre, France).
Arthritis therapy
The ability to treat animal models of arthritis effectively by
gene delivery was confirmed by a number of investigators.
Intra-articular gene transfer of IL-1 and TNF inhibitors such
as sIL-R, IL-1Ra and sTNF-R, and immunosuppressive
cytokines such as IL-4 and viral IL-10, as well as antago-
nists of NF-κB (S Makarov, University of North Carolina,
USA) were able to block inflammation as well as additional
pathologies in murine, rat and rabbit models of arthritis.
Importantly, the levels of these proteins necessary to
confer a therapeutic effect following intra-articular gene
delivery were far less than those needed for therapeutic
efficacy following injection of recombinant protein. Inter-
estingly, the van den Berg laboratory demonstrated that
use of an IL-1 responsive promoter to drive IL-1Ra expres-
sion resulted in a better therapeutic effect in vivo com-
pared to a constitutive promoter that gave higher
expression. These results suggest that localized, regulated
expression of IL-1Ra is highly effective in blocking
disease. Taken together, the significant therapeutic effects
observed following intra-articular gene transfer at relatively
low doses of expression warrant the further development
of this approach to the gene therapy of arthritis and
related joint disorders. Adenoviral vectors may also be
delivered systemically, and interesting results for the deliv-
ery of several immunomodulatory genes were described
by E Quattrocchi (Kennedy Institute, UK).
As an alternative to treating arthritis by local, intra-articular
gene delivery, several investigators presented the use of
genetically modified immune system cells to modulatec
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disease progression. J Mountz (University of Alabama, USA)
demonstrated that systemic delivery of antigen-presenting
cells expressing Fas ligand and pulsed with type II collagen
was able to suppress development of collagen-induced
arthritis. In addition, systemic delivery of dendritic cells mod-
ified to express IL-4 was able to completely reverse estab-
lished murine collagen-induced arthritis (P Robbins). The
Fathman laboratory (A Nakajima, I Tarner, Stanford Univer-
sity, USA) presented evidence that genetically modified, col-
lagen-specific T cells could home to joints and confer a
therapeutic effect in a murine arthritis model. Similarly, Y
Chernajovsky (University of London, UK) demonstrated the
ability to modify T cells to express a single chain anti-colla-
gen antibody to target the cells to joints.
In addition to treating inflammation and joint swelling by
gene transfer, several groups have focused on blocking or
eliminating the hyperplastic synovium. U Müller-Ladner
(University of Regensburg, Germany) presented results
from a SCID (severe combined immunodeficiency) human
model, showing that gene transfer of IL-1Ra and IL-10 to
RA synovial fibroblasts blocks their invasion into normal
cartilage as well as blocking cartilage degradation. Inter-
estingly, the inclusion of sTNF-R gene transfer with IL-1Ra
and IL-10 did not improve the therapeutic efficacy, but
instead reduced it. S Gay (University Hospital Zurich,
Switzerland) and T Pap (University Hospital Magdeburg,
Germany) provided evidence that inhibition of cathepsins
B and L and matrix metalloproteinase-1 expression using
gene transfer of antisense or ribozymes to RA synovial
cells was also therapeutic. Chondroprotection can also be
achieved by overexpressing inhibitors of the proteinases
that degrade the matrix of cartilage (W Van der Laan,
Leiden University, The Netherlands; G Schett, Vienna,
Austria), and by the transfer to chondrocytes of antiapop-
totic genes (C Coumil, Vandoeuvre, France).
Several groups also examined the ability to eliminate
hyperplastic synovium by intra-articular gene transfer of
certain apoptotic proteins. H Zhang (University of Pennsyl-
vania, USA) reported efficacy in human synovium
implanted into SCID mice. T Oligino provided evidence
that adenovirus-mediated gene transfer of several apop-
totic genes, such as those encoding Fas ligand, TRAIL,
p53 and granzyme B, resulted in extensive apoptosis in a
rabbit model of arthritis. Interestingly, p53 was the most
effective gene product at inducing synovial apoptosis in
the rabbit model and also significantly inhibited inflamma-
tion through an unknown mechanism within 24 hours after
injection. In contrast, P Tak (Amsterdam, The Netherlands)
presented evidence that the identical p53 adenovirus was
unable to confer a therapeutic effect in a rat model of
arthritis. The reasons for this discrepancy between the
effect of Ad–p53 in rabbit and rat models is unclear, but
may represent the timing of injection or the level of infec-
tion of synovium.
Bone healing
Several investigators presented the use of gene transfer to
accelerate bone healing. The enhancement of the bone
healing process by transient, local gene delivery repre-
sents an attractive, achievable and appropriate application
of gene therapy. A Baltzer (Dusseldorf, Germany) pre-
sented evidence that adenovirus-mediated delivery of
bone morphogenetic protein (BMP)-2 and transforming
growth factor (TGF)-β1 directly into a critically sized seg-
mental bone defect in rabbit femora led to complete boney
union within 12 weeks. In contrast to the in vivo delivery
method, D Gazat (Hebrew University, Jerusalem)
described the use of ex vivo administration of MSCs,
genetically modified to express BMP-2, to facilitate bone
repair. Scaffolds to assist in the delivery of the genetically
modified MSCs into the bone defects are being devel-
oped and tested.
The ability to prevent bone loss in a murine model of
osteoporosis by systemic delivery of IL-1Ra by adenoviral
infection also was presented (A Baltzer). Using a similar
approach, D Bolon (Amgen, USA) demonstrated that sys-
temic expression of the soluble decoy receptor osteopro-
tegerin (OPG) resulted in significantly more bone volume
and fewer osteoclasts in ovariectomized mice. Interest-
ingly, the systemic expression of OPG persisted for an
extended period of time following intravenous injection of
the Ad–OPG vector into mice, suggesting that OPG
might also have effects on the immune response to virally
infected cells.
Cartilage repair
M Brittberg (Goteborg University, Sweden) presented the
results of a clinical trial using nongenetically modified
chondrocytes that demonstrated the feasibility of perform-
ing autologous transplantation. Sixty-one patients were fol-
lowed for a mean of 7.4 years, with 50 patients showing
clinical improvement. Cartilage histology of the repair
could be obtained with a second-look arthroscopy, and in
8 out of 12 cases, hyaline cartilage was observed. P
Hernigou (Creteil, France) presented clinical data in hip
osteonecrosis, where bone marrow cells containing MSCs
were injected into the femoral head. Using the experimen-
tal SCID/hu model, D Gazat and D Noel (Montpellier,
France) presented data on injection of engineered MSCs
expressing BMP-2 under the control of a Tet-regulated
promoter that resulted in cartilage formation in the knee
joint. G Gross (Braunschweig, Germany) and C Jor-
gensen presented evidence that MSCs can be induced to
differentiate into cartilage if modified to express BMP-2,
cartilage-derived morphogenetic protein (CDMP)-1 and 2,
Sox-9 or the T-box family of transcription factors. Cartilage
repair was observed, but limited by endochondral bone
formation after 4 weeks follow-up. The increase in angio-
genesis observed after BMP-2 expression might be
involved in the osteogenesis.
Available online http://arthritis-research.com/content/3/5/289Matrix is critical for appropriate three-dimensional culture
of progenitor cells, and for maintaining their chondral dif-
ferentiation. A Facchini (Bologna, Italy) reported the use of
a hyaluronic acid matrix as a support for the growth of
immortalized chondrocytes that produced collagen II for
the first 4 weeks. The future of cartilage repair may be the
development of hybrid cartilage combining the matrix, the
genes encoding growth factors and the progenitor cells.
Gene therapy to facilitate cartilage repair has been limited
by the inability to deliver therapeutic genes directed to
cartilage in vivo. As presented by S Ghivizzani (Harvard
Medical School, USA), intra-articular expression of certain
chondrogeneic factors by virus-mediated gene transfer to
synovium is one way to obviate this problem. Transfer of
insulin-like growth factor (IGF)-1 and BMP-2 genes to the
synovium in rabbits’ knee joints increased matrix synthesis
by the adjacent articular cartilage. Transfer of the TGF-β1
gene in this way, however, led to severe adverse effects.
Thus it appears advantageous to deliver the therapeutic
genes directly into the cartilage defect, and Ghivizzani dis-
cussed various approaches to achieving this.
Clinical trials
The meeting also highlighted the current status of clinical
trials for arthritis and related disorders. C Evans (Harvard
Medical School, USA) presented the results of the first
‘gene therapy for arthritis’ clinical trial. The Phase I trial
was designed to demonstrate safety and feasibility of
transferring the gene for IL-1Ra to knuckle (MCP) joints in
a three-dose escalation study enrolling nine patients. The
ex vivo gene transfer of IL-1Ra was well tolerated in all
nine patients treated, with evidence of intra-articular gene
expression. P Wehling (Dusseldorf, Germany) presented
similar results from three patients treated in an ongoing
trial in Dusseldorf. There was a lively discussion regarding
the ethical considerations regarding attempting clinical
trials of a gene therapy for a nonlethal disease. Evans
made a compelling argument for the Phase I trial in that it
was based on extensive preclinical and safety efficacy
data, and was reviewed and approved by an Institutional
Review Board, an Institutional Biosafety Committee, the
Recombinant DNA Advisory Committee of the National
Institutes of Health, the United States Food and Drug
Administration, the Director of the National Institutes of
Health, and an External Review Board. Moreover, the posi-
tive results from the Phase I study should engender Phase
II trials to evaluate efficacy of intra-articular gene transfer.
Future directions
The Second International Meeting on Gene and Cell Ther-
apies of Arthritis and Related Disorders provided consid-
erable optimism for the future. Clearly, gene therapy for
joint and bone disorders is feasible, safe and effective in
animal models. Moreover, it appears to be safe in a
recently completed Phase I study. What is still needed is
the development of better vectors for direct gene transfer
in vivo that allow for repeat dosing and long-term, regu-
lated gene expression. In addition, although stem cell
biology is progressing at a rapid rate, significantly more
details of the signaling events that regulate differentiation
of stem cells into bone or cartilage are needed. Finally, fol-
lowing appropriate rigorous safety testing and review, it
will be important to start moving some of the well devel-
oped, effective preclinical approaches into the clinic. The
field of gene therapy for joint and bone diseases is clearly
moving forward and we believe there is a high likelihood
that exciting progress will be presented at the Third Inter-
national Meeting on Gene and Cell Therapies of Arthritis
and Related Disorders, which is tentatively scheduled for
the Spring of 2003.
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